Navigation Links
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Date:9/8/2008

s of the study and it was not a major reason for discontinuation during the trial.

About liraglutide

Once-daily liraglutide is the first human Glucagon-Like Peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the US as well as a marketing authorization application to the European Medicines Agency in Europe, for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 15, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) program includes five randomized, controlled, double-blind phase 3a studies, involving about 4,000 people with type 2 diabetes in 40 countries.

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit '/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro ... Alliance (HITRUST) under its Common Security Framework (CSF). ... Security and Privacy Manager, "We appreciate this rigorous, ... of commitment that this certification signifies. Our business ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s internal ...
(Date:8/21/2014)... 2014  Henry Schein, Inc. (NASDAQ: HSIC ), ... to office-based dental, animal health and medical practitioners, announced today ... September: , September 4, 2014 – Baird 2014 ... 12:50 p.m. ET , September 8, 2014 – ... York , NY at 1:25 p.m. ET ...
(Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
Breaking Medicine Technology:ScriptPro Achieves HITRUST Certification 2Henry Schein To Present At Two Investor Conferences In September 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... YORK, May 19, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0503653/Pharmaceutical-Management-of-Obesity-Technical-Insights.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... a lot of research and product development ...
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ... from ten separate studies at the American Society of ... 2011 at McCormick Place in Chicago.  The company markets ... which is clinically validated to predict chemotherapy benefit as ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Management of Obesity (Technical Insights) 2Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 7
(Date:8/21/2014)... Strongly influenced by their self-interest, humans ... are no consequences, researchers in Georgia State University’s ... could imply that humans are less concerned than ... said. Their findings are published in the journal ... unfairness is affected by their self-interest, indicating the ...
(Date:8/21/2014)... Recently, Skmen.com, a distinguished garment supplier, has updated its product ... dresses . From today until August 31, all clients can ... they are shopping at the company’s online store. , ... the newest quality standards; they are guaranteed to be fashionable ... ladies can also access the other cheap items in its ...
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers ... its new selection of Trillium Parkas for 2014. Moreover, ... these fashionable and comfortable items are available at discounted ... last until September 01. , The CEO says ... Canada Goose Trillium Parkas for new and old ...
(Date:8/21/2014)... 22, 2014 BambooIndustry.com is an internationally ... company has recently unveiled its new collection of elegant ... made for customers who are looking for high quality ... are offered with great savings (up to 29 percent ... access these cheap products. , The company’s bamboo ...
(Date:8/21/2014)... the University of Michigan,s Transplant Center was able to ... for transplant by about 20 percent. , The results ... detail the impact of more than 10 years of ... quality and viability of organs donated after circulatory determination ... number of donated organs available, so the use of ...
Breaking Medicine News(10 mins):Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 3Health News:Charming Girls’ Casual Dresses Now Released by Distinguished Garment Company Skmen.com 2Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Buy Elegant Bamboo Floorings from Internationally Well-known Supplier BambooIndustry.com 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2
... 7th International Symposium on GnRH Analogs in Cancer ... development of fertility drugs. Organon scientists have succeeded ... a hybrid subunit, which extends FSH's active life. ... longer active life will mean fewer injections for ...
... version of Annals of Internal Medicine has suggested that the ... boost energy, is posing a threat to people's health and ... to the supplement. The study used data gathered by the ... of the total calls received, an// estimated 80 per cent ...
... van den Dolder at the University of Nijmegen has shown ... with the help of specially prepared titanium mesh and bone ... bone fracture in a rat. They allowed bone marrow cells ... being stimulated by the bone// marrow cells. They found that ...
... of Public Health now reveals that caregiving may be associated ... who care for a disabled or ill spouse have an ... from a long-running Nurses' Health Study, which had collected data ... between 46 and 71. They found that those who devoted ...
... PNAS that understanding and treating cholesterol-related illnesses in humans ... receptor in the cells of mice that protects them ... of cerebrotendinous xanthomatosis (CTX), a rare and often fatal ... Pregnane X receptor (PXR)// is present in humans but ...
... decades now, about having spotless white teeth and a ... problem that is caused by aging and colored molecules ... people used corrosive nitric acid, which bleached teeth white ... destroyed them! However, dentists have now discovered many easy ...
Cached Medicine News:Health News:New fertility drug development techniques by Organon 2Health News:Bones repair themselves with bone marrow cells 2
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
Attain LV Leads. Navigate minimally angled veins with little to moderate tortuosity....
Medicine Products: